Cancer BiologybioRxivPreprint
Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
V. W. Rebecca, M. Xiao, A. Kossenkov…·M. Herlyn
The paper identifies dasatinib as effective in restoring BRAFi/MEKi antitumor efficacy in 70% of resistant PDX models by targeting proteins involved in therapy escape.
DOI 10.1101/2023.01.20.524923